Vitamin D and Multiple Sclerosis

2011 ◽  
Vol 25 (1) ◽  
pp. 75-84 ◽  
Author(s):  
Nicole Marie Summerday ◽  
Sherrill J. Brown ◽  
Douglas R. Allington ◽  
Michael P. Rivey
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Animal Studies ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Epidemiological Evidence ◽  
Short Term ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
True Relationship

There has been growing interest in determining environmental risk factors that may play a role in the development or progression of multiple sclerosis (MS). Epidemiological evidence and data from human and animal studies have shown an association between low serum vitamin D levels and an increased incidence of MS and that supplementation with vitamin D may protect against MS development and/or disease relapses. The most appropriate vitamin D dosage for patients with MS is unclear, but investigators have proposed that serum vitamin D concentrations between 75 and 100 nmol/L (30-40 ng/mL) are optimal to achieve favorable clinical outcomes. Vitamin D supplemented in doses up to 3000 International Units (IU) daily may be necessary to achieve these levels in many patients, and doses of 500 to 800 IU daily appear to be necessary to maintain desired serum vitamin D levels. Short-term supplementation with doses up to 40 000 IU daily has been found to be safe. However, larger and longer clinical studies are needed to assess whether a true relationship exists between serum vitamin D concentrations and MS and to determine a safe and effective amount of vitamin D supplementation.

scholarly journals No correlation was observed between vitamin D levels and disability of patients with multiple sclerosis between latitudes 18° and 30° South

2017 ◽  
Vol 75 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Yara Dadalti Fragoso ◽  
Tarso Adoni ◽  
Soniza Vieira Alves-Leon ◽  
Samira L. Apostolos-Pereira ◽  
Walter Oleschko Arruda ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Large Population ◽  
Serum Vitamin ◽  
Serum Levels ◽  
Serum Vitamin D ◽  
Control Subjects ◽  
Vitamin D Levels ◽  
The Mean ◽  
25 Oh Vitamin D

ABSTRACT Objective: Vitamin D has taken center stage in research and treatment of multiple sclerosis (MS). The objective of the present study was to assess the serum vitamin D levels of a large population of patients with MS and controls living in a restricted tropical area. Methods: Data from 535 patients with MS and 350 control subjects were obtained from 14 cities around the Tropic of Capricorn. Results: The mean serum 25-OH vitamin D level was 26.07 ± 10.27 ng/mL for the control subjects, and 28.03 ± 12.19 ng/mL for patients with MS. No correlation was observed between vitamin D levels and the disability of patients over the disease duration. Conclusion: At least for the region around the Tropic of Capricorn, serum levels of vitamin D typically are within the range of 20 to 30 ng/mL for controls and patients with MS.

Association Between cardiometabolic risk factor and responsiveness to vitamin D supplementation: A New Approach using Artificial Neural Network analysis

2020 ◽  
Author(s):  
Elahe Allahyari ◽  
Parichehr Hanachi ◽  
Seyed Jamal Mirmoosavi ◽  
Gordon A. Ferns ◽  
Afsane Bahrami ◽  
...  
Keyword(s):  
Vitamin D ◽  
Risk Factor ◽  
Cardiometabolic Risk ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Cardiometabolic Risk Factor ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Artificial Neural

Abstract BackgroundAccumulating data have highlighted the prominence of supplementation as an effective approach for vitamin D deficiency. But individuals vary in their response to vitamin D supplementation. In this study, the effect of cardiometabolic risk factors were evaluate on magnitude of response to vitamin D supplementation by using novel statistical analysis, artificial neural networks(ANNs).Methods608 participants aged between 12 to 19 years old were assed in this prospective interventional study. Nine vitamin D capsules containing 50000IU vitamin D/weekly were given to all participants over the 9 week period. The change in serum 25(OH)D level was calculated as the difference between post-supplementation and basal levels. Suitable ANNs model were selected between different algorithms in the hidden and output layers and different numbers of neurons in the hidden layer. Then, the major determinants in predicting response to vitamin D supplementations were identified (Trial registration: IRCT201509047117N7; 2015-11-25; Retrospectively registered)ResultsSigmoid in both hidden and output layers with 4 hidden neurons had acceptable sensitivity, specificity and accuracy area under the ROC curve in our study. Baseline serum vitamin D (30.4%), waist to hip ratio (10.5%), BMI (10.5%), systolic blood pressure (8%), heart rate (6.4%), and waist circumference (6.1%) were the greatest importance in predicting the response in serum vitamin D levels. ConclusionWe provide the first attempt to relate anthropometric specific recommendations to attain serum vitamin D targets. With the exception of cardiometabolic risk factor, the relative importance of other factors and the mechanisms by which these factors may affect the response requires further analysis in future studies.

scholarly journals A170 VITAMIN D IN IBD PATIENTS – A RETROSPECTIVE REVIEW

2020 ◽  
Vol 3 (Supplement_1) ◽  
pp. 35-36
Author(s):  
R A MacMillan ◽  
T Ponich
Keyword(s):  
Vitamin D ◽  
Bone Density ◽  
Disease Severity ◽  
Regression Coefficient ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Serum Vitamin D ◽  
Mayo Score ◽  
Vitamin D Levels ◽  
Low Serum

Abstract Background Vitamin D is a critical factor in bone remodelling, calcium absorption and may promote anti-inflammatory cytokines in the gut. Inflammatory bowel disease (IBD) is associated with a reduction in serum Vitamin D levels and a chronic inflammatory state, both of which are strong risk factors for bone density loss affecting IBD patients. Despite European and North American IBD maintenance guidelines for Vitamin D monitoring and bone density scans, there are limited North American investigations into factors influencing serum Vitamin D levels in the IBD patient population specifically. Aims We investigated whether patient demographics, disease severity indexes and/or inflammatory markers were linked to low serum Vitamin D levels in our IBD patients. We also established the extent of Vitamin D serum deficiencies and supplementation rates in our IBD patients. Methods A retrospective chart review of a single clinician’s practice at London Health Science Centre, Victoria Hospital, over the past 20 months, was performed to: 1) assess the frequency of low serum 25-OH Vitamin D (25-OH D) in the IBD patient population and 2) determine whether patient disease severity was linked to lower 25-OH D levels. A multivariate regression analysis was performed assessing Crohn’s Disease (CD) or Ulcerative Colitis (UC) patient factors: age, sex, disease duration, seasonality, current pharmacologic treatments, past surgeries, CD Activity Index, UC Mayo score, C-reactive protein, and fecal calprotectin (Fcal) level. Results 175 IBD patients had at least one 25-OH D measurement with 71 patients actively on Vitamin D therapy. Of UC and CD patients who were not on Vitamin D therapy, 63% (17/27) and 79% (61/77) were 25-OH D deficient, respectively. 25-OH D levels in the CD population was associated with Vitamin D supplementation (regression coefficient [RC] 23.99, 95% confidence interval [CI] 14.54 to 33.45), summer season ([RC] 9.90, [CI] 0.56 to 19.24), and past bowel resection ([RC] -10.61, [CI] -20.48 to -0.76). 25-OH D levels in the UC population was associated with Vitamin D supplementation (regression coefficient [RC] 47.23, 95% confidence interval [CI] 27.62 to 66.83), and Mayo severity scores ([RC] -23.01, [CI] -41.82 to -4.20). Fcal (78 patients) was inversely associated with 25-OH D levels but the trend was not significant. Conclusions Overall, 25-OH D levels were lower in both the UC and CD patient populations relative to the already deficient Canadian population. However, IBD patients are responsive to Vitamin D supplementation. Tools with more objective evidence of disease severity such as UC Mayo score and fcal should be prioritized for identifying the IBD population requiring supplementation. Funding Agencies None

KLOTO rs1207588 allelic variant affects serum vitamin D levels in multiple sclerosis patients

2019 ◽  
Vol 493 ◽  
pp. S614
Author(s):  
L. Agnello ◽  
C. Scazzone ◽  
B. Lo Sasso ◽  
G. Bivona ◽  
G. Iacolino ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Serum Vitamin ◽  
Allelic Variant ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Multiple Sclerosis Patients

scholarly journals Role of Vitamin D in Parkinson’s Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Khanh Lương ◽  
Lan Nguyễn
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Mhc Class Ii ◽  
Serum Vitamin ◽  
Renin Angiotensin System ◽  
Vitamin D Supplementation ◽  
Heme Oxygenase 1 ◽  
Serum Vitamin D ◽  
Vitamin D Levels

Parkinson’s disease (PD) is the second most common form of neurodegeneration in the elderly population. Clinically, it is characterized by tremor, rigidity, slowness of movement, and postural imbalance. A significant association between low serum vitamin D and PD has been demonstrated, suggesting that elevated vitamin D levels might provide protection against PD. Genetic studies have helped identify a number of proteins linking vitamin D to PD pathology, including the major histocompatibility complex (MHC) class II, the vitamin D receptor (VDR), cytochrome P450 2D6 (CYP2D6), chromosome 22, the renin-angiotensin system (RAS), heme oxygenase-1 (HO-1), poly(ADP-ribose) polymerase-1 gene (PARP-1), neurotrophic factor (NTF), and Sp1 transcription factor. Vitamin D has also been implicated in PD through its effects on L-type voltage-sensitive calcium channels (L-VSCC), nerve growth factor (NGF), matrix metalloproteinases (MMPs), prostaglandins (PGs) and cyclooxygenase-2 (COX-2), reactive oxygen species (ROS), and nitric oxide synthase (NOS). A growing body of evidence suggests that vitamin D supplementation may be beneficial for PD patients. Among the different forms of vitamin D, calcitriol (1,25-dihydroxyvitamin D3) is best indicated for PD, because it is a highly active vitamin D3 metabolite with an appropriate receptor in the central nervous system (CNS).

Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes

2013 ◽  
Vol 20 (2) ◽  
pp. 147-155 ◽  
Author(s):  
Vittorio Martinelli ◽  
Gloria Dalla Costa ◽  
Bruno Colombo ◽  
Dacia Dalla Libera ◽  
Alessandro Rubinacci ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Serum Vitamin ◽  
Brain Magnetic Resonance Imaging ◽  
Hydroxyvitamin D ◽  
Serum Vitamin D ◽  
Clinically Isolated Syndromes ◽  
Vitamin D Levels ◽  
Magnetic Resonance Imaging Mri

Background: Growing evidence suggests that vitamin D deficiency may be one of the most important environmental factors for the development of multiple sclerosis (MS). Objectives: The objectives of this paper are to evaluate serum 25-hydroxyvitamin D (25(OH)D) levels in patients with clinically isolated syndromes (CIS) and to examine whether they are related to MS risk. Methods: This is a retrospective study of 100 CIS patients hospitalized from 2000 to 2009 at San Raffaele Hospital, Milan, Italy. We evaluated baseline 25(OH)D level as well as clinical, brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data. Results: A total of 52% of CIS patients had vitamin D deficiency (25(OH)D < 50 nmol/l). During follow-up (median: 7.17 years), 55 patients developed clinically definite MS (CDMS). Patients with very low (< 10th percentile) and low (< 25th percentile) 25(OH)D levels were particularly at risk of CDMS (HRs (95% CIs): 2.12 (0.91–4.96) and 1.61 (0.85–3.03), respectively), while no further reduction in the HRs of disease was observed at high levels of 25(OH)D. This association was even stronger after adjustment for additional risk factors for CDMS development (HRs (95% CIs) for 25(OH)D levels < 10th and 25th percentiles: 3.34 (1.32–8.45) and 2.04 (0.96–4.36), respectively). Conclusion: Low serum vitamin D is associated with increased MS risk in patients with CIS.

scholarly journals Association Between Serum Vitamin D Levels and Frequency of Relapses in Patients With Multiple Sclerosis

Cureus ◽  
2021 ◽  
Author(s):  
Farah Mansoor ◽  
Vikash Kumar ◽  
Suneel Kumar ◽  
Navneet Kaur ◽  
Sidra Naz ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Serum Vitamin ◽  
Serum Vitamin D ◽  
Vitamin D Levels

scholarly journals Evaluation of efficacy of a nanoparticle based vitamin D formulation in correction of vitamin D levels in patients with documented deficiency or insufficiency of vitamin D

2017 ◽  
Vol 3 (3) ◽  
pp. 486
Author(s):  
Kishore A. Manek
Keyword(s):  
Vitamin D ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Open Label ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Post Marketing ◽  
Sufficient Vitamin ◽  
To Receive

<p><strong>Background:</strong> In India more than 90% of apparently healthy Indians have subnormal 25(OH) D levels. To maintain sufficient vitamin D level, apart from sunlight and food containing vitamin D, supplementation with vitamin D is also required. The objective of this study was to find out effectiveness of nanoparticle based vitamin D formulations in patient of vitamin D deficiency and insufficiency</p><p><strong>Methods:</strong> This was a prospective, open label, single arm, non-comparative, dose response post-marketing efficacy study (PMS) – phase-4 study to find the effectiveness of a nanoparticle based vitamin D formulation in adult patients between 18 to 65 years of either gender, attending/visiting the study site with documented deficiency or insufficiency of vitamin D (&lt;30 ng/ml) or sign and symptoms of deficiency or insufficiency of vitamin D. Each subject planned to receive 60,000 IU of nanoparticle based vitamin D, once weekly, for 8 weeks orally. Serum 25(OH) D levels were measured at baseline, 4 and 8 week.</p><p><strong>Results:</strong> The mean baseline serum 25[OH] D levels were 15.90. After treatment with nanoparticle based vitamin D there was a significant increase in the serum vitamin D levels at 4 weeks (41.03) and 8 weeks (31.38) (p&lt;0.0001). Patients who have received treatment for at least 4 weeks’ period (n=38), the improvement (serum 25[OH] D &gt;30 ng/ml) was seen in 84.2% patients (n=32) at the end of 4 weeks itself. There is significant increased (&lt;0.0001) in the physical component scores of the SF-12 QOL questionnaire after 8 weeks of therapy.</p><p><strong>Conclusions:</strong> Nanoparticle based formulation of vitamin D<sub>3</sub> is effective and safe in correction of vitamin D levels in patients with documented deficiency or insufficiency of vitamin D. Also the safety and tolerability is well accepted and reported good to excellent by patients and physician.</p><p> </p>

scholarly journals Influence of Supplementary Vitamin D on the Prognostic Pathway of Type1 Diabetes Among Children

2021 ◽  
Vol 14 (1) ◽  
pp. 303-309
Author(s):  
Mostafa Hassan Ragab ◽  
Eman Monir Sherif ◽  
Nadia Badawy Abd- El Gawad ◽  
Safaa Mohamed Elserougy ◽  
Eman Essam Shaban ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Intake Assessment ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Egyptian Children ◽  
The Impact

Diabetes is one of the commonest chronic diseases worldwide. Vitamin D deficiency showed to be increasing, and have a potential role in autoimmune diseases among which in type 1 diabetes. The aim The aim of the study was to assess the impact of oral vitamin D supplementation on blood glucose (HbA1C) in T1DM patients and to find out the role of vitamin D as a biomarker for follow of T1DM patients compared to HbA1C. Subjects and methods: A randomized interventional clinical study was designed. The study enrolled 60 children patients with T1DM. Only 45 children continued to the end of study. Initial (pre-intake) assessment included history taking, clinical examination, and measurement of serum 25-OH vitamin D3 and serum HbA1C. These children received oral vitamin D supplements for 3 months then post-intake assessment were done again. Results: The study showed that serum vitamin D was deficient among Egyptian children and adolescents with T1DM (mean 11.4±3.4 ng/ml). , 53.33% of the patients had vitamin D deficiency with a 35.6% had insufficiency and 11.11% were VD sufficient. Patients received oral vitamin D supplementation for 3 months after which marked improvement in the levels of serum vitamin D levels and HA1C, 87.5% and 86.5% respectively.

Sign in / Sign up

Export Citation Format

Share Document